On the stock market since 2021, it operates in the world of health and science. It has 54 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $2.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 36 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $18.6M against $2.3M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, FEMY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FEMY is a high-risk stock — not yet profitable, and its future rides on its product catching on.